CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Ibrutinibdrug
Likely dose
Ibrutinib 560 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02321540
NCT02321540Phase 2Completed
CompareCT.gov

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

M.D. Anderson Cancer Center·interventional·Posted Dec 22, 2014·Updated Oct 25, 2023

In Brief

A Phase 2 clinical trial evaluating Ibrutinib for Lung Cancer. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The goal of Part 1 of this clinical research study is to find the highest dose of (Imbruvica) ibrutinib that can be given to patients with non-small cell lung cancer (NSCLC). The goal of Part 2 of this clinical research study is to learn if the dose of ibrutinib found in Part 1 can help to control the disease. The safety of this drug will also be studied in both parts of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsPharmacyclics LLC., National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 22, 2014
Enrollment StartMar 31, 2015
Primary CompletionSep 16, 2021
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 11.5 years ago

Interventions

Ibrutinibdrug

Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle. Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily.